Akari Therapeutics Plc: Akari Therapeutics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference

NEW YORK and LONDON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases

Related Keywords

London ,City Of ,United Kingdom ,Mike Moyer ,Eliza Schleifstein ,Rachelle Jacques ,Nasdaq ,Akari Therapeutics Plc Nasdaq ,Cantor Medical ,Aesthetic Dermatology ,Diagnostic Conference ,Miami December ,Late Stage Stories ,Shake Things ,Orphan Drug ,Fast Track ,Rare Pediatric Disease ,Hakari ,Herapeutics ,Articipate ,Cantor ,Fitzgerald ,Medical ,Aesthetic ,Ermatology ,Ophthalmology ,Edtech ,Iagnostic ,Conference ,